TB PAN-NET
Pan-European network for the study and clinical management of drug resistant tuberculosis
| Coordinatore | UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 14˙115˙409 € |
| EC contributo | 10˙998˙270 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2014-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
IT (MILANO) | coordinator | 979˙381.00 |
| 2 |
FORSCHUNGSZENTRUM BORSTEL
Organization address
address: Parkallee 1-40 contact info |
DE (BORSTEL) | participant | 1˙740˙747.00 |
| 3 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 1˙677˙700.00 |
| 4 |
EUROPEAN RESPIRATORY SOCIETY
Organization address
address: Avenue Sainte Luce 4 contact info |
CH (LAUSANNE) | participant | 743˙960.00 |
| 5 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 695˙469.00 |
| 6 |
VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINES SANTARISKIU KLINIKOS
Organization address
address: SANTARISKIU G 2 contact info |
LT (VILNIUS) | participant | 567˙725.00 |
| 7 |
FOLKHALSOMYNDIGHETEN
Organization address
address: NOBELS VAG 18 contact info |
SE (SOLNA) | participant | 548˙960.00 |
| 8 |
UNIVERSITA' DEGLI STUDI DI SIENA
Organization address
address: VIA BANCHI DI SOTTO 55 contact info |
IT (SIENA) | participant | 400˙700.00 |
| 9 |
AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
Organization address
address: VIA PERGOLESI 33 contact info |
IT (MONZA) | participant | 383˙030.00 |
| 10 |
FONDAZIONE SALVATORE MAUGERI CLINICA DEL LAVORO E DELLA RIABILITAZIONE
Organization address
address: Via Salvatore Maugeri 4 contact info |
IT (PAVIA) | participant | 373˙096.00 |
| 11 |
University of Medicine and Dentistry of New Jersey
Organization address
address: "Bergen Street, suite 540 65" contact info |
US (Newark) | participant | 371˙995.00 |
| 12 |
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS
Organization address
address: Avenue Louis-Casai 71 contact info |
CH (COINTRIN GENEVE) | participant | 310˙909.00 |
| 13 |
LATVIJAS INFEKTOLOGIJAS CENTRS (INFECTOLOGY CENTER OF LATVIA)
Organization address
address: LINEZERA IELA 3 contact info |
LV (RIGA) | participant | 273˙926.00 |
| 14 |
Hain Lifescience GmbH
Organization address
address: Hardwiesenstrasse contact info |
DE (NEHREN) | participant | 241˙100.00 |
| 15 |
INSTITUT PASTEUR DE LILLE FONDATION
Organization address
address: 1 Rue du professeur Calmette contact info |
FR (LILLE) | participant | 211˙989.00 |
| 16 |
SIHTASUTUS TARTU UELIKOOLI KLIINIKUM
Organization address
address: PUUSEPA 1A contact info |
EE (TARTU) | participant | 183˙800.00 |
| 17 |
SPITALUL DE PNEUMOFTIZIOLOGIE BRASOV
Organization address
address: ALEEA DEALUL SPIRII 12 contact info |
RO (BRASOV) | participant | 172˙200.00 |
| 18 |
MONTESSORI GUIDO
Organization address
address: Via Montaione 33G contact info |
IT (Rome) | participant | 164˙208.00 |
| 19 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 145˙080.00 |
| 20 |
PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE
Organization address
address: Nationalestraat 155 contact info |
BE (ANTWERPEN) | participant | 139˙500.00 |
| 21 |
INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE
Organization address
address: Rue Juliette Wytsman 14 contact info |
BE (BRUXELLES) | participant | 139˙288.00 |
| 22 |
VILNIAUS UNIVERSITETAS
Organization address
address: UNIVERSITETO G. 3 contact info |
LT (VILNIUS) | participant | 104˙400.00 |
| 23 |
"INSTITUTUL DE PNEUMOFTIZIOLOGIE ""MARIUS NASTA"""
Organization address
address: Sos. Viilor sector 5 90 contact info |
RO (Bucharest) | participant | 97˙129.00 |
| 24 |
NASJONALT FOLKEHELSEINSTITUTT
Organization address
address: Lovisenberggata 8 contact info |
NO (OSLO) | participant | 71˙954.00 |
| 25 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 63˙000.00 |
| 26 |
Bolnisnica Golnik Klinicni oddelek za pljucne bolezni in alergijo
Organization address
address: GOLNIK 36 contact info |
SI (GOLNIK) | participant | 52˙320.00 |
| 27 |
HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO
Organization address
address: ROCKEFELLEROVA 7 contact info |
HR (ZAGREB) | participant | 51˙000.00 |
| 28 |
RIGAS AUSTRUMU KLINISKA UNIVERSITATES SLIMNICA SIA
Organization address
address: HIPOKRATA IELA 2 contact info |
LV (RIGA) | participant | 47˙384.00 |
| 29 |
INSTYTUT GRUZLICY I CHOROB PLUC
Organization address
address: UL. PLOCKA 26 contact info |
PL (WARSZAWA) | participant | 46˙320.00 |
| 30 |
"Rutgers, The State University of New Jersey - RBHS"
Organization address
address: "65 Bergen Street, Suite 538" contact info |
US (Newark) | participant | 0.00 |
| 31 |
National Tuberculosis and Infectious Diseases University Hospital
Organization address
address: Antakalnio str. 77 contact info |
LT (Vilnius) | participant | 0.00 |
| 32 |
SMITTSKYDDSINSTITUTET
Organization address
address: Nobels vaeg 18 contact info |
SE (SOLNA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB) facing the EU. The objective will be attained through the establishment of a European consortium of expert partners with extensive experience in the conduct of basic and clinical research relating to MDR-TB, TB control and epidemiology. This Consortium will achieve this by: • Conducting an extensive and focused programme of basic/clinical research to improve the diagnosis and management of MDR-TB • Develop a broad training curriculum leading to the creation of a new generation of scientists and clinicians expert in the management of drug resistant TB • Create field sites across the EU with the capacity for evaluating new diagnostic systems and novel drug therapies on behalf of European industry and government • Establish a unified and robust quality assurance mechanism for the accurate and rapid diagnosis of drug resistance and develop appropriate safety standard for European health care workers • Improving our understanding of the transmission of MDR-TB at the molecular level and host-related risk factors for its development, • The Consortium will disseminate its findings and analyses widely to the benefit of specialists, general health care staff, EU governments, NGOs and health policy makers. This will provide researchers and clinicians with appropriate knowledge and improved tools to fight MDR-TB, and assist European industry in the development of new diagnostics and treatments. Consortium outputs will assist governments in the development and implementation of appropriate health and social policies to limit and control the spread of MDR-TB within the member states of the EU. Internationally, these objectives will assist countries bordering the EU and international agencies such as the WHO and ECDC in reducing the impact of drug resistance.'
Introduzione (Teaser)
Tuberculosis represents one of the major medical challenges in history. Although curable for decades, improper treatment has led to the emergence of multi-drug resistant bacteria.
Descrizione progetto (Article)
There are over a million multi-drug resistant cases of tuberculosis every year, 10 % of which exhibit resistance to the two most important classes of second line drugs.
The EU-funded 'Pan-European network for the study and clinical management of drug resistant tuberculosis' (http://www.tbpannet.org/ (TB PAN-NET)) project brought together multi-disciplinary expertise from all over Europe to identify what drives drug resistance in different settings. Particular emphasis was given on clinical and social risk factors such as immune-depression, immigration and poverty.
TB PAN-NET worked on the development of novel tools and the identification of biomarkers for tuberculosis diagnosis. Researchers discovered that serum miRNAs could serve as biomarkers for diagnosing as well as monitoring disease progression. Quantitative molecular assays were also developed for monitoring early treatment response and the preliminary evaluation of personalised regimens.
To elucidate multi-drug resistance and bacterial fitness, scientists analysed the transcriptional regulatory network in drug-sensitive and -resistant Mycobacterium tuberculosis strains. They classified for the first time the mutations that cause resistance to specific drugs and set up assays for their detection. In addition, they generated genetically engineered Mycobacterium strains resistant to specific second line anti-tubercular drugs that will serve as tools for future research.
Considerable effort went into training and capacity building in tuberculosis-endemic countries to perform clinical and diagnostic trials. Equally important was the training of European clinicians on the international standards and requirements of clinical management and control of resistant tuberculosis.
Collectively, the TB PAN-NET consortium combined basic science, clinical and epidemiological studies to understand the emergence and transmission patterns of drug-resistant tuberculosis. The generated information should be particularly useful to health policy makers in disease management, transmission control and treatment.